ecancer catches up with Josep Tabernero on exploring new targets in GI cancer as well as the WIN Consortium launch of WINTHER, an original academic and international clinical trial

The Mass General Cancer Center hosted an international, multi-disciplinary workshop on March 4 and 5 to explore how advances in…

• VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with…

Recently captured at the 2011 ASCO meeting, Joan Seoane, Director of the Vall d´Hebron Institute of Oncology´s (VHIO) Translational Research Programme talks to ecancermedicalscience

Barcelona, 17 July 2015. – Last week, 10 July, marked the second Vall d´Hebron Research Institute (VHIR) Health Innovation Contest,…

The prize-giving ceremony was held on Thursday 7 April at the head office of the ABC newspaper in Madrid.

Dr. José Baselga, one of Spain’s most prestigious international oncologists and a key figure in the research and treatment of breast cancer, has been distinguished as “Physician of the Year”. This first edition of the ABC Health Awards recognises the outstanding work of medical professionals and institutions in the public and private health sectors. 
 

Many of VHIO´s leading clinical investigators are currently participating at the 2017 Annual Meeting of the American Society of Clinical…

Findings reported from the open-label, single-group, and mulitcenter phase II PAMELA trial, published last week in The Lancet Oncology*, have…

Source: American Association for Cancer Research (AACR) PHILADELPHIA — Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies,…

The International Association for the Study of Lung Cancer (IASLC), has recently announced ten new expert additions to its Board…

Recently published in the journal Oncoscience, Laura Soucek, Principal Investigator of VHIO´s Mouse Models of Cancer Therapies Group, and two…

ICREA – the Catalan Institution for Research and Advanced Studies, founded back in 2001 with the support of the Catalan…

World Cancer Day is the singular initiative under which the UICC (Union for International Cancer Control), its members, partners, supporters…

• Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in…

Published today in The New England Journal of Medicine, a multi-center phase I clinical study conducted across 11 countries, co-authored by Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors Group, represents an important step forward in the treatment of patients with ALK-rearranged lung cancer.